SEC EDGARSEP 251 min read$TBPH

MITCHELL DEAN J sold (to issuer) 97,213 shares of TBPH

MITCHELL DEAN J sold (to issuer) 97,213 shares of Theravance Biopharma, Inc. (TBPH) across 2 trades on 2026-09-23.

Original reporting

SEC EDGAR · MITCHELL DEAN J

Published Sep 25, 2026, 12:32 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 25, 2026, 12:56 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$TBPH

Bearish

medium confidence

Mentioned

$TBPH

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TBPHBearishLow

Why it matters

The transaction may slightly depress the stock due to perceived insider sentiment, but the scale is limited.

Market read

Relevant for traders monitoring insider activity; limited broader market impact.

What to watch

Potential upcoming corporate actions or financing that prompted the director to exit.

Relevance 4/10Novelty 4/10Timing: after-hours 2026-09-23

Background

SEC Form 4 filings disclose insider transactions; this filing reports a director's complete exit from Theravance Biopharma.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TBPHBearishMedium confidence

Context

Director Mitchell Dean sold 97,213 shares of Theravance Biopharma, reducing his holdings to zero.

Expected impact

Minor downward pressure on TBPH price in the short term.

Evidence & confidence

A director exiting completely may be viewed negatively, yet the share count is small for a listed biotech, limiting impact.

Market effects

Sector

Minimal effect on the biotech sector; similar insider sales are common and rarely move the sector.

Regional

No notable regional impact; the filing is specific to the company.

Global

Low global relevance; only relevant to investors tracking TBPH.

Counterpoint

What could challenge this read

The sale could be unrelated to company fundamentals and merely a personal liquidity need.

Key entities

Company
Theravance Biopharma, Inc.
Biopharmaceutical company listed on Nasdaq under TBPH.
Individual
Mitchell Dean J.
Director of Theravance Biopharma who sold his entire shareholding.

Read at source ← All news

SEP 28

$ZYMEHigh

Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Int

Zymeworks (ZYME) completed its acquisition of Theravance Biopharma, adding the respiratory drug YUPELRI to its portfolio. The move aims to provide steady revenue and support growth. Zymeworks trades at a high P/S ratio of 53.9, reflecting growth expectations, but remains unprofitable. Its GF Score is 61, indicating moderate fundamental health with strengths in valuation and momentum but weaknesses in profitability and growth.

gurufocus.com3 min

SEP 23

$ZYMEHighAI 8/10

Zymeworks Inc.: Zymeworks Completes Acquisition of Theravance Biopharma

Zymeworks Inc. (ZYME) completed its acquisition of Theravance Biopharma, integrating the company to diversify its revenue streams. Zymeworks will host a conference call on September 28 to discuss the transaction details. The acquisition aims to advance Zymeworks' strategy of combining innovative R&D with commercial and royalty-based cash flows.

finanznachrichten.de2 min

SEP 23

$TBPHHigh

Theravance Biopharma, Inc. (TBPH): Completion of Acquisition or Disposition of Assets

Theravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of September 22, 2026 (this “ Agreement ”), is entered into by and between Zymeworks Inc., a Delaware corporation (“ Parent ”), and Computershare Inc., a Delaware corporation (“ Comput

SEC EDGAR 8-K2 min

AUG 10

$TBPHMedAI 8/10

Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash

Theravance Biopharma reported Q2 2026 revenue of $20.7M, all from its Viatris collaboration, up 11% YoY. GAAP net loss was $5.9M. Cash and marketable securities were $387.7M at June 30, 2026. The company said a Zymeworks acquisition is expected to close in H2 2026, and it cited restructuring cost savings.

tradingview.com2 min

AUG 10

$TBPHHigh

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Theravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update · Previously announced acquisition by Zymeworks expected to close in second half of 2026 · YUPELRI ® Collaboration Revenue increased 11% year-over-year 1 , from $18

SEC EDGAR 8-K6 min

JUL 21

$ZYMEHighAI 9/10

USA: Zymeworks acquisisce Theravance Biopharma, focus su YUPELRI per diversificare il portafoglio e accelerare la crescita – Padovanews

Zymeworks Inc. agreed to acquire Theravance Biopharma, adding YUPELRI (revefenacin) for COPD. The deal values Theravance at $17/share, with a $350 million non-recourse note and $219 million cash plus Theravance’s estimated $360 million net cash at closing. YUPELRI U.S. net sales were $266.6M in 2025. Expected close in H2 2026.

padovanews.it5 min